Skip to Content

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

Published Date: April 16, 2025

In this video, Dr. Joyce O’Shaughnessy, a renowned breast cancer expert, and Mina Guirguis, PharmD, discuss the use of Nerlynx (neratinib) in treating early-stage HER2-positive breast cancer after initial trastuzumab therapy. They explore its role in reducing the risk of recurrence in patients and delve into strategies for managing side effects.

Patient advocate Amenda Lacy shares her personal experience with Nerlynx, providing insight into the patient journey and the importance of supportive care.

Topics covered include:

  • Overview of Nerlynx and its role in reducing the risk of recurrence in early-stage HER2-positive breast cancer.

  • Guidance on managing side effects, particularly diarrhea, to improve patient adherence and treatment outcomes.

  • Insights on how Nerlynx targets the HER2 pathway to inhibit cancer cell growth.

  • Discussion on the clinical benefits of Nerlynx for patients at high risk for recurrence.

  • Patient perspective on treatment, with a focus on Amenda Lacy’s journey and the importance of supportive care.

 

View Prescribing Information

Sponsored by